Mintz and Co. is a company.
Key people at Mintz and Co..
Mintz and Co. was founded by Sergey Gribov (CTO, Co-founder).
Mintz and Co. was founded by Sergey Gribov (CTO, Co-founder).
Key people at Mintz and Co..
Mintz (full name: Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.) is an AmLaw 100 law firm headquartered in Boston with over 600 attorneys across offices in the US and Toronto, specializing in private equity, venture capital, emerging companies, investment funds, and portfolio company support.[9][2][7] It acts as a business accelerator for innovative companies in life sciences, technology, healthcare, energy, and financial services, providing full-service legal advice on fund formation, financings, M&A, exits, regulatory compliance, IP protection, and more.[1][3][4] The firm's mission centers on delivering high-touch, commercially grounded counsel to private equity sponsors, VC firms, startups, and institutional investors, with a strong emphasis on cross-border transactions involving US and Canadian markets.[1][4] Mintz influences the startup ecosystem through initiatives like MintzEdge, a startup accelerator offering legal tools and investor introductions, and by representing VC-backed companies from seed to IPO.[2][3]
Founded in 1933 in Boston as a real estate and banking practice with an early niche in theaters and motion pictures, Mintz evolved into a national powerhouse by expanding into litigation, transactional work, and high-growth sectors.[2] Key growth phases included bolstering financial markets in New York, regulatory expertise in Washington, DC, and tech/biotech hubs in California (San Francisco, San Diego) and Toronto since the mid-2000s, with Boston still housing over half its associates.[2][7] The firm developed specialized practices in private equity, venture capital, and emerging companies, creating ML Strategies for lobbying and MintzEdge for startups; it now ranks among the top US firms for startups, VC financings, and fund formations.[2][3][5]
Mintz rides trends in private equity middle-market buyouts, VC financings for cybersecurity/biotech (e.g., obesity/diabetes therapies), and growth equity in profitable late-stage firms, capitalizing on post-JOBS Act crowdfunding and secondary markets.[1][3][8] Timing aligns with rising cross-border investments and regulatory shifts, where its DC lobbying arm (ML Strategies) and IP/tech prowess in coastal hubs position it to navigate energy transition, health innovation, and AI-driven tech amid economic volatility.[2][7] The firm shapes the ecosystem by accelerating startups via MintzEdge, facilitating $20M+ deals, and enabling fund managers/investors to scale platforms, fostering innovation in high-regulation sectors like life sciences and telecom.[3][5]
Mintz will likely deepen cross-border PE/VC mandates amid global fund consolidation and AI/healthtech booms, expanding growth equity and secondaries as institutional capital seeks middle-market yields.[1][4] Trends like sustainability-focused buyouts and oversubscribed biotech rounds (e.g., Syntis Bio) will propel its practice, with MintzEdge amplifying startup throughput.[3][8] Its influence may evolve toward more operating-partner roles for portfolio companies, solidifying its status as a coast-to-coast accelerator for tomorrow's innovators—echoing its 90-year evolution from Boston roots to worldwide dealmaker.[2][7]
